Stock TCBP TC BIOPHARM (HOLDINGS) PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials TC Biopharm (Holdings) Plc

Equities

TCBP

US87807D4007

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.53 USD -2.55% Intraday chart for TC Biopharm (Holdings) Plc +3.45% -51.74%
Apr. 25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Apr. 23 European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 3.024 1.353
Enterprise Value (EV) 1 1.012 0.6913
P/E ratio -1.57 x -0.13 x
Yield - -
Capitalization / Revenue 0.79 x -
EV / Revenue 0.26 x -
EV / EBITDA -0.09 x -0.05 x
EV / FCF -121,204 x -56,526 x
FCF Yield -0% -0%
Price to Book -118 x 0.95 x
Nbr of stocks (in thousands) 47.5 543
Reference price 2 63.66 2.490
Announcement Date 5/1/23 4/1/24
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 3.427 1.979 1.979 3.845 -
EBITDA 1 -5.95 -6.022 -6.475 -11.16 -13.61
EBIT 1 -6.641 -6.887 -7.287 -11.92 -14.24
Operating Margin -193.78% -348.05% -368.28% -310.08% -
Earnings before Tax (EBT) 1 -6.894 -6.63 -14.98 -3.11 -6.996
Net income 1 -6.068 -5.458 -13.58 -1.39 -5.907
Net margin -177.07% -275.84% -686.12% -36.15% -
EPS 2 -338.7 -288.4 -129.9 -40.45 -19.12
Free Cash Flow - -0.7429 -4.304 -8.351 -12.23
FCF margin - -37.54% -217.5% -217.21% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 7/26/21 7/26/21 5/13/22 5/1/23 4/1/24
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S1 2023 Q2
Net sales 1 - -
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income 0.6287 -
Net margin - -
EPS 18.64 -
Dividend per Share - -
Announcement Date 12/12/22 11/8/23
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 2.48 2.28 15.1 - -
Net Cash position 1 - - - 2.01 0.66
Leverage (Debt/EBITDA) -0.4172 x -0.3781 x -2.327 x - -
Free Cash Flow - -0.74 -4.3 -8.35 -12.2
ROE (net income / shareholders' equity) - 185% 136% 16.8% -392%
ROA (Net income/ Total Assets) - -49.5% -59.6% -78.5% -88%
Assets 1 - 11.04 22.79 1.77 6.712
Book Value Per Share 2 -142.0 -33.40 -158.0 -0.5400 2.610
Cash Flow per Share 2 53.40 7.480 15.00 101.0 2.390
Capex 1 2.03 0.03 0.02 0.24 0.11
Capex / Sales 59.14% 1.76% 1.01% 6.26% -
Announcement Date 7/26/21 7/26/21 5/13/22 5/1/23 4/1/24
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TC BIOPHARM (HOLDINGS) PLC Stock TC Biopharm (Holdings) Plc
-51.74% 4.89M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TCBP Stock
  4. Financials TC Biopharm (Holdings) Plc